Physician profile
Suzanne Cotter
NPI 1609804137
$627.54
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $250 · 2023: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $102.13 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $101.53 | 2022-2023 | Breztri |
| Amgen INC. | $81.22 | 2022-2023 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.40 | 2022-2023 | Synjardy, Jardiance, Glyxambi |
| Radius Health, INC. | $62.44 | 2023 | Tymlos |
| Lilly USA, LLC | $58.42 | 2023 | Mounjaro, Jardiance |
| Abbvie INC. | $39.73 | 2022-2023 | Vraylar |
| Biohaven Pharmaceutical Holding Company Ltd. | $30.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.70 | 2022 | |
| Glaxosmithkline, LLC. | $16.04 | 2022 | |
| Pfizer INC. | $14.81 | 2023 | |
| Merck Sharp & Dohme LLC | $14.35 | 2023 | Gardasil 9, M-M-R II, Proquad |
| Otsuka America Pharmaceutical, INC. | $12.77 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Cotter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.